The risk of developing MS and other demyelinating diseases is 3 times greater in individuals diagnosed with EBV-positive IM.

I foolishly was in a crowded indoor location and got COVID (for the third time). I thought about getting Paxlovid. But I ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Almost without fail, a person will enter the examination room, make no introduction, and launch into a series of questions or ...

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.

Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...

Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED). Batoclimab, ...

Myrobalan's experimental therapy MRO-002 is a GPR17 antagonist that's made to promote myelin repair in people with MS and ...

The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease ...